← INTENSITY THERAPEUTICS, INC. (INTS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
INTENSITY THERAPEUTICS, INC. (INTS)
Biological Products, (No Diagnostic Substances) · market cap $13M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Intensity Therapeutics (INTS) is a micro-cap clinical-stage biotech with 5 employees and a ~$13M market cap, running a Phase 3 trial of Eribulin in soft tissue sarcoma and a Phase 2 program of INT230-6 in breast cancer. The company holds $10.2M in cash against an estimated 16.8-month runway, with no catalysts currently on the public calendar and no recent data readouts disclosed.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Eribulin | Phase 3 | Sarcoma,Soft Tissue |
| INT230-6 | Phase 3 | Breast Cancer |
| anti-PD-1 antibody | Phase 2 | Breast Cancer |
| anti-CTLA-4 antibody | Phase 2 | Breast Cancer |
Price & technical context
3-month
-29.7%
6-month
-38.8%
12-month
-46.9%
52-wk range
$3.14–$33.00
vs 50-day MA
-16.9%
vs 200-day MA
-40.4%
Realized vol
193.0%
Max drawdown
-94.0%
Daily closes through 2026-10-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INTS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.